Source: NASDAQ Stocks / 01 Nov 2024 03:56:28 America/New_York
Fintel reports that on October 31, 2024, Morgan Stanley downgraded their outlook for Biogen (LSE:0R1B) from Overweight to Equal-Weight.
https://www.nasdaq.com/articles/morgan-stanley-downgrades-biogen-lse-0r1b